Promising effects of eribulin for cystic lung metastases of epithelioid sarcoma: a case report. Issue 8 (September 2018)

• Record Type: Journal Article
• Authors: Iwai, Tadashi; Hoshi, Manabu; Oebisu, Naoto; Shimatani, Akiyoshi; Takada, Naoki; Nakamura, Hiroaki
• Is Part Of: Anti-cancer drugs. Volume 29:Issue 8(2018)
• Publication Date: 2018-09
• Subjects: epithelioid sarcoma -- eribulin -- lung metastasis -- progression-free survival; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000657
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Epithelioid sarcoma (ES) is a rare and aggressive type of soft tissue sarcoma with resistance to systemic chemotherapy. Therefore, new treatment options are required for patients with advanced ES. Eribulin is a novel potential treatment option for patients with inoperative sarcoma. We herein report a case of a 27-year-old Japanese man with cystic lung metastases from an ES in the left forearm, resulting in long-term stable disease. A solid, metastatic sarcomatous nodule appeared in the right lung, as shown by computed tomography, within the first 2 months after surgery. After the lung metastasis was detected, he underwent a total of 37 cycles of chemotherapy in six regimens. However, multiple cystic lung metastases had progressed in segments S6 and S9/10; hence, eribulin treatment was initiated. After two courses of eribulin, the excess fluid density material in the cystic metastases was completely absorbed, and an additional four courses of treatment resulted in shrinkage of the cystic metastases. These effects lasted for 13 months without severe adverse effects. Cystic lung metastases are an extremely rare consequence of soft tissue sarcoma, and eribulin is one of the most promising options for the treatment of advanced ES.